NEW ORLEANS -- Among patients with heart failure, conduction system pacing-guided cardiac resynchronization therapy was associated with improvements in left ventricular ejection fraction (LVEF) ...

Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) ...

Abbott (NYSE:ABT) today shared new study findings supporting its pulsed field ablation (PFA) and conduction system pacing ...

New research highlights postnatal regeneration limits and pathological remodeling of the cardiac conduction system after myocardial infarction, uncovering mechanisms behind clinical arrhythmogenesis ...

Discordant results from two trials comparing conduction system pacing with biventricular pacing for cardiac resynchronization therapy (CRT) leave open the question of whether conduction system pacing ...

New research in Sweden has produced a "blueprint" revealing how the human heart is built during prenatal development. It offers insights that could lead to improved prenatal care and new treatments ...

Physiologic pacing of the His-Purkinje conduction system is feasible in patients who require a permanent pacemaker following TAVR and this alternative pacing method did not interfere with ejection ...

Medtronic has secured FDA approval for its OmniaSecure defibrillation lead to be used in conduction system pacing, the first device cleared for left bundle branch area placement. The small, lumenless ...

Cardiac physiologic pacing, also known as cardiac resynchronization therapy, is indicated in patients with heart failure, reduced left ventricular ejection fraction (LVEF) of 50% or less, and either a ...

Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates DUBLIN, Oct. 17, 2022 ...

Please provide your email address to receive an email when new articles are posted on . Medtronic announced its cardiac lead received an expanded indication from the FDA for left bundle branch area ...

A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...